A Phase 4 interventional study of Ivermectin + colchicine and Colchicine in COVID-19, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-04-07.
Sponsored by Ain Shams University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in COVID-19 by Ain Shams University — 1 open to participants now, 1 under way, none of them phase 3. COVID-19 · Ain Shams University.
Among the 38 studies in COVID-19 by Ain Shams University, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is one of 12 that started in 2021, is one of 3 in phase 4, and was the 29th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →1 of the 38 studies in COVID-19 by Ain Shams University is open now. Recruiting first, the newest first:
Ain Shams University
Ages 25–60
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8 · Phase 4 3
First in 2020; this study’s year is marked. 12 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 135 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 90 across the 18 interventional studies, 95 across the 20 observational. Of the 22 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 38 studies in COVID-19 by Ain Shams University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study will be to investigate the efficacy of use of combination of Ivermectin and colchicine on severity and outcome Of COVID 19 infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In addition to the local standard of care for COVID 19 patients, the patient will receive: Ivermectin + Colchicine
Drug: Ivermectin + colchicine
In addition to the local standard of care for COVID 19 patients, the patient will receive: Colchicine
Drug: Colchicine
Patients will receive Standard care
Drug pages: IvermectinStudies of IvermectinIvermectin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
In addition to the local standard of care for COVID 19 patients, the patient will receive Ivermectin + colchicine
In addition to the local standard of care for COVID 19 patients, the patient will receive colchicine
length of oxygen requirement
Time frame: 3 months
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Nov 2021 to primary completion in Feb 2022, 3 months.
Of 145 non-industry phase 4 interventional studies under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 3 months is below that.
Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 4 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.